In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy. (15th October 2021)
- Record Type:
- Journal Article
- Title:
- In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy. (15th October 2021)
- Main Title:
- In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy
- Authors:
- Zhang, Xuan
Zhang, Yan
Zheng, Haiping
He, Yufeng
Jia, Honglin
Zhang, Liyuan
Lin, Chunjie
Chen, Shuang
Zheng, Junfeng
Yang, Qunfang
Liu, Tao
Pan, Xichun
Zhang, Haigang
Wang, Chenhui
Ren, Lei
Shan, Wenjun - Abstract:
- Abstract: Metastasis is the leading cause of death in cancer patients. Eliciting anti-tumor immune responses against lung metastasis is hindered by the immunosuppressive microenvironment. This study explored a biomimetic nanoformulation, comprising a nanovaccine (OP) that delivers tumor antigens and adjuvants spatially and temporally in a virus-like manner, and a pulmonary surfactant-biomimetic liposome with an immunomodulator, JQ1 (PS-JQ1). The findings of this study showed that intratracheal administration of OP+PS-JQ1 activated lung immune cells without concomitant excess inflammation, enhanced tumor antigen cross-presentation, generated a significantly high antigen-specific CD8 + T cell response, and reshaped the immunocellular composition in B16 melanoma tumor-bearing lung. OP+PS-JQ1 nanoformulation exhibited a striking immunotherapeutic efficacy, induced local and systemic tumor suppression, improved survival of mice, initiated immune memory that prevents recurrence of secondary tumors. This stable and nontoxic nanoformulation provides a simple, flexible, and robust strategy for augmenting anti-tumor immunity for metastatic cancer. Statement of significance: Egg glue proteins are produced by female insects, which can make the eggs firmly attached to the oviposition sites, not affected by wind and rain. However, genes encoding insect egg glue proteins have not yet been reported, and the molecular mechanism underpinning their adhesion is still unknown. Our study makes aAbstract: Metastasis is the leading cause of death in cancer patients. Eliciting anti-tumor immune responses against lung metastasis is hindered by the immunosuppressive microenvironment. This study explored a biomimetic nanoformulation, comprising a nanovaccine (OP) that delivers tumor antigens and adjuvants spatially and temporally in a virus-like manner, and a pulmonary surfactant-biomimetic liposome with an immunomodulator, JQ1 (PS-JQ1). The findings of this study showed that intratracheal administration of OP+PS-JQ1 activated lung immune cells without concomitant excess inflammation, enhanced tumor antigen cross-presentation, generated a significantly high antigen-specific CD8 + T cell response, and reshaped the immunocellular composition in B16 melanoma tumor-bearing lung. OP+PS-JQ1 nanoformulation exhibited a striking immunotherapeutic efficacy, induced local and systemic tumor suppression, improved survival of mice, initiated immune memory that prevents recurrence of secondary tumors. This stable and nontoxic nanoformulation provides a simple, flexible, and robust strategy for augmenting anti-tumor immunity for metastatic cancer. Statement of significance: Egg glue proteins are produced by female insects, which can make the eggs firmly attached to the oviposition sites, not affected by wind and rain. However, genes encoding insect egg glue proteins have not yet been reported, and the molecular mechanism underpinning their adhesion is still unknown. Our study makes a significant contribution to the literature as it identifies the sequence, structure, adhesive property, and mechanism of silkworm egg glue protein. Furthermore, it outlines key insights into the structure-function relationships associated with egg glue proteins. We believe that this paper will be of interest to the readership of your journal as it identifies the first complete sequence of insect egg glue proteins, thereby highlighting their potentials future applications in both the biomedical and technical fields. Graphical abstract: Image, graphical abstract … (more)
- Is Part Of:
- Acta biomaterialia. Volume 134(2021)
- Journal:
- Acta biomaterialia
- Issue:
- Volume 134(2021)
- Issue Display:
- Volume 134, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 134
- Issue:
- 2021
- Issue Sort Value:
- 2021-0134-2021-0000
- Page Start:
- 633
- Page End:
- 648
- Publication Date:
- 2021-10-15
- Subjects:
- Biomimetic -- Nanoformulation -- Lung metastasis -- Iimmunotherapy
Biomedical materials -- Periodicals
610.28 - Journal URLs:
- http://www.sciencedirect.com/science/journal/17427061 ↗
http://www.elsevier.com/wps/find/journaldescription.cws%5Fhome/702994/description ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.actbio.2021.07.055 ↗
- Languages:
- English
- ISSNs:
- 1742-7061
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0602.900500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19913.xml